P53 in the Game of Transposons

Overview

Journal Bioessays

Publisher Wiley

Specialties Biology
Cell Biology
Molecular Biology

Date 2016 Sep 20

PMID 27644006

Citations 14

Authors

Annika Wylie

Amanda E Jones

John M Abrams

Affiliations

Soon will be listed here.

Abstract

Throughout the animal kingdom, p53 genes function to restrain mobile elements and recent observations indicate that transposons become derepressed in human cancers. Together, these emerging lines of evidence suggest that cancers driven by p53 mutations could represent "transpospoathies," i.e. disease states linked to eruptions of mobile elements. The transposopathy hypothesis predicts that p53 acts through conserved mechanisms to contain transposon movement, and in this way, prevents tumor formation. How transposon eruptions provoke neoplasias is not well understood but, from a broader perspective, this hypothesis also provides an attractive framework to explore unrestrained mobile elements as inciters of late-onset idiopathic disease. Also see the video abstract here.

Citing Articles

Inheritance of Stress Responses via Small Non-Coding RNAs in Invertebrates and Mammals.

Ow M, Hall S Epigenomes. 2024; 8(1).

PMID: 38534792 PMC: 10969415. DOI: 10.3390/epigenomes8010001.

Affinity-Based Interactome Analysis of Endogenous LINE-1 Macromolecules.

Di Stefano L, Saba L, Oghbaie M, Jiang H, McKerrow W, Benitez-Guijarro M Methods Mol Biol. 2022; 2607:215-256.

PMID: 36449166 DOI: 10.1007/978-1-0716-2883-6_12.

Virus-Induced Membrane Fusion in Neurodegenerative Disorders.

Osorio C, Sfera A, Anton J, Thomas K, Andronescu C, Li E Front Cell Infect Microbiol. 2022; 12:845580.

PMID: 35531328 PMC: 9070112. DOI: 10.3389/fcimb.2022.845580.

Bridging Tumorigenesis and Therapy Resistance With a Non-Darwinian and Non-Lamarckian Mechanism of Adaptive Evolution.

Catania F, Ujvari B, Roche B, Capp J, Thomas F Front Oncol. 2021; 11:732081.

PMID: 34568068 PMC: 8462274. DOI: 10.3389/fonc.2021.732081.

How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor.

Ho T, Tan B, Lane D Int J Mol Sci. 2019; 21(1).

PMID: 31861395 PMC: 6982169. DOI: 10.3390/ijms21010013.

References

Christophorou M, Ringshausen I, Finch A, Swigart L, Evan G . The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature. 2006; 443(7108):214-7. DOI: 10.1038/nature05077. View

Peterson J, Bass B, Jue D, Rodriguez A, Abrams J, McCall K . Noncanonical cell death pathways act during Drosophila oogenesis. Genesis. 2007; 45(6):396-404. DOI: 10.1002/dvg.20306. View

Brodsky M, Nordstrom W, Tsang G, Kwan E, Rubin G, Abrams J . Drosophila p53 binds a damage response element at the reaper locus. Cell. 2000; 101(1):103-13. DOI: 10.1016/S0092-8674(00)80627-3. View

Wylie A, Lu W, DBrot A, Buszczak M, Abrams J . p53 activity is selectively licensed in the Drosophila stem cell compartment. Elife. 2014; 3:e01530. PMC: 3949305. DOI: 10.7554/eLife.01530. View

Meek D . Mechanisms of switching on p53: a role for covalent modification?. Oncogene. 2000; 18(53):7666-75. DOI: 10.1038/sj.onc.1202951. View

Ross R, Weiner M, Lin H . PIWI proteins and PIWI-interacting RNAs in the soma. Nature. 2014; 505(7483):353-359. PMC: 4265809. DOI: 10.1038/nature12987. View

Baudino L, Yoshinobu K, Morito N, Santiago-Raber M, Izui S . Role of endogenous retroviruses in murine SLE. Autoimmun Rev. 2010; 10(1):27-34. DOI: 10.1016/j.autrev.2010.07.012. View

Valente L, Gray D, Michalak E, Pinon-Hofbauer J, Egle A, Scott C . p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 2013; 3(5):1339-45. DOI: 10.1016/j.celrep.2013.04.012. View

Brodsky M, Weinert B, Tsang G, Rong Y, McGinnis N, Golic K . Drosophila melanogaster MNK/Chk2 and p53 regulate multiple DNA repair and apoptotic pathways following DNA damage. Mol Cell Biol. 2004; 24(3):1219-31. PMC: 321428. DOI: 10.1128/MCB.24.3.1219-1231.2004. View

10.

Volkman H, Stetson D . The enemy within: endogenous retroelements and autoimmune disease. Nat Immunol. 2014; 15(5):415-22. PMC: 4131434. DOI: 10.1038/ni.2872. View

11.

Michalovitz D, Halevy O, Oren M . p53 mutations: gains or losses?. J Cell Biochem. 1991; 45(1):22-9. DOI: 10.1002/jcb.240450108. View

12.

Perl A, Fernandez D, Telarico T, Phillips P . Endogenous retroviral pathogenesis in lupus. Curr Opin Rheumatol. 2010; 22(5):483-92. PMC: 5314925. DOI: 10.1097/BOR.0b013e32833c6297. View

13.

Peters M, DeLuca C, Hirao A, Stambolic V, Potter J, Zhou L . Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila. Proc Natl Acad Sci U S A. 2002; 99(17):11305-10. PMC: 123252. DOI: 10.1073/pnas.172382899. View

14.

Stetson D, Medzhitov R . Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity. 2006; 24(1):93-103. DOI: 10.1016/j.immuni.2005.12.003. View

15.

Jin S, Kalkum M, Overholtzer M, Stoffel A, Chait B, Levine A . CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals. Genes Dev. 2003; 17(3):359-67. PMC: 195984. DOI: 10.1101/gad.1047003. View

16.

DBrot A, Kurtz P, Regan E, Jakubowski B, Abrams J . A platform for interrogating cancer-associated p53 alleles. Oncogene. 2016; 36(2):292. DOI: 10.1038/onc.2016.190. View

17.

Vousden K, Prives C . P53 and prognosis: new insights and further complexity. Cell. 2005; 120(1):7-10. DOI: 10.1016/j.cell.2004.12.027. View

18.

Vousden K, Lane D . p53 in health and disease. Nat Rev Mol Cell Biol. 2007; 8(4):275-83. DOI: 10.1038/nrm2147. View

19.

Freed-Pastor W, Mizuno H, Zhao X, Langerod A, Moon S, Rodriguez-Barrueco R . Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012; 148(1-2):244-58. PMC: 3511889. DOI: 10.1016/j.cell.2011.12.017. View

20.

Kassiotis G . Endogenous retroviruses and the development of cancer. J Immunol. 2014; 192(4):1343-9. PMC: 3925786. DOI: 10.4049/jimmunol.1302972. View